Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients

NCT00714376 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

OTHER

Sponsor class

Stopped Prematurely terminated due to financial considerations

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel

Sponsor

CHU de Quebec-Universite Laval